Pharmaceuticals
Search documents
Eli Lilly stock rises after $7.8B Centessa deal—bet on sleep drugs
Invezz· 2026-03-31 16:24
Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion, marking a significant expansion of the drugmaker's neuroscience portfolio into sleep medicine. Under th... ...
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio
Yahoo Finance· 2026-03-31 16:20
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio Proactive uses images sourced from Shutterstock Biogen Inc (NASDAQ:BIIB, XETRA:IDP) will acquire Apellis Pharmaceuticals Inc (NASDAQ:APLS) for $41 per share in cash, in a deal valued at approximately $5.6 billion, it was announced on Tuesday. Apellis shareholders will also receive a nontransferable contingent value right (CVR) worth up to $4 per share if certain global sales milestones for SYFOVRE are achieved. Shares ...
Jim Cramer Highlights Johnson & Johnson Stock’s “Free Fall” and Rise Despite Lawsuits
Yahoo Finance· 2026-03-31 16:04
Johnson & Johnson (NYSE:JNJ) was among the stocks Jim Cramer highlighted, along with his latest game plan as the oil-shock-driven sell-off continues. Cramer mentioned the stock during the episode and said: Now, what I suggest you do is look at Johnson & Johnson. Until it became clear that the impact wouldn’t be as bad, the stock was in free fall, and then when it was clear, it went from $140 to $230 almost in the blink of an eye. I think the same thing will happen here. Stock market data. Photo by Bura ...
Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza
ZACKS· 2026-03-31 16:00
Key Takeaways Biogen shares rose after the FDA approved a higher-dose Spinraza regimen for SMA treatment.New dosing reduces frequency and shows improved motor function in DEVOTE study patients.Approval may help Biogen counter competition that has pressured Spinraza sales recently.Shares of Biogen (BIIB) rose 2% on Monday after the company announced that the FDA approved a higher dose of its blockbuster spinal muscular atrophy (SMA) drug Spinraza.The new dosing regimen simplifies administration by offering t ...
Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders
Prnewswire· 2026-03-31 16:00
<!doctype html> <!-- For structured data --> <!-- For language declaration --> Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders <!-- Additional Authorable Meta tags --> Accessibility StatementSkip NavigationMILWAUKEE, March 31, 2026 /PRNewswire/ -- LLP is investigating Centessa (NASDAQ: CNTA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Lilly.Click hereto lea ...
Jupiter Neurosciences to Present at Emerging Growth Conference on April 2
Globenewswire· 2026-03-31 16:00
JUPITER, FL, March 31, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to announce that it has been invited to present its clinical and commercial progress at the Emerging Growth Conference 91 on April 2, 2026, at 10:15 AM ET. Jupiter invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive ...
Shareholder Alert: The Ademi Firm investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
Prnewswire· 2026-03-31 16:00
<!doctype html> <!-- For structured data --> <!-- For language declaration --> Shareholder Alert: The Ademi Firm investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders <!-- Additional Authorable Meta tags --> Accessibility StatementSkip NavigationMILWAUKEE, March 31, 2026 /PRNewswire/ -- Ademi LLP is investigating Apellis (NASDAQ: APLS) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Biogen.Click here ...
West Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and Obesity
Prnewswire· 2026-03-31 15:46
The work at this site is part of West Vantageâ"¢, the company's comprehensive contract services business. West Vantageâ"¢ provides customers with a single-source solution spanning product conceptualization, development, device manufacturing and assembly, packaging, validation, analytical testing, and regulatory support. Through this integrated approach, West helps pharmaceutical and biotechnology partners accelerate time to market by delivering reliable, scalable solutions that support the global supply of ...
Here’s Why You Don’t Bet Against This Dividend King
Yahoo Finance· 2026-03-31 15:30
Quick Read Johnson & Johnson (JNJ) raised its quarterly dividend from $1.24 to $1.30 per share (5% increase) and extended its consecutive dividend hike streak to 63 years, yielding 2.14% annually with a sustainable 46.7% payout ratio and $19.7 billion in free cash flow. Pfizer (PFE) carries payout ratio risk at 118.6% despite higher yield, while Merck (MRK) lacks Johnson & Johnson’s breadth and reliability track record. Johnson & Johnson’s diversified portfolio of medicines, medical devices, and consume ...
Here's Why You Don't Bet Against This Dividend King
247Wallst· 2026-03-31 15:30
Here's Why You Don't Bet Against This Dividend King - 24/7 Wall St. S&P 5006,437.70 +1.39% Dow Jones45,713.20 +0.99% Nasdaq 10023,324.80 +1.61% Russell 20002,453.53 +1.64% FTSE 10010,172.40 +0.90% Nikkei 22551,667.30 +1.25% Stock Market Live March 31, 2026: S&P 500 (SPY) Pops on News Trump Could End War Investing Here's Why You Don't Bet Against This Dividend King By Rich DupreyPublished Mar 31, 11:30AM EDT Quick Read Johnson & Johnson (JNJ) raised its quarterly dividend from $1.24 to $1.30 per share (5% ...
